tetano
Editor, Senior Moderator
Clin Infect Dis
. 2022 Jun 10;ciac472.
doi: 10.1093/cid/ciac472. Online ahead of print.
Multiplex Detection of Antibody Landscapes to SARS-CoV-2/Influenza/Common Human Coronaviruses Following Vaccination or Infection with SARS-CoV-2 and Influenza
Zhu-Nan Li[SUP] 1 [/SUP], Feng Liu[SUP] 1 [/SUP], Stacie Jefferson[SUP] 1 [/SUP], Lauren Horner[SUP] 1 [/SUP], Paul Carney[SUP] 1 [/SUP], Michael D L Johnson[SUP] 2 [/SUP], Jennifer P King[SUP] 3 [/SUP], Emily T Martin[SUP] 4 [/SUP], Richard K Zimmerman[SUP] 5 [/SUP], Karen Wernli[SUP] 6 [/SUP], Manjusha Gaglani[SUP] 7 8 [/SUP], Mark Thompson[SUP] 1 [/SUP], Brendan Flannery[SUP] 1 [/SUP], James Stevens[SUP] 1 [/SUP], Terrence Tumpey[SUP] 1 [/SUP], Min Z Levine[SUP] 1 [/SUP]
Affiliations
Abstract
Background: SARS-CoV-2 and influenza viruses continue to co-circulate, representing two major public health threats from respiratory infections with similar clinical presentations. SARS-CoV-2 and influenza vaccines can also now be co-administered. However, data on antibody responses to SARS-CoV-2 and influenza co-infection, and vaccine co-administration remains limited.
Methods: We developed a 41-plex antibody immunity assay that can simultaneously characterize antibody landscapes to SARS-CoV-2/influenza/common human coronaviruses. We analyzed sera from 840 individuals (11-93 years), including sera from reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 positive (n = 218) and negative (n = 120) cases, paired sera from SARS-CoV-2 vaccination (n = 29) and infection (n = 11), and paired sera from influenza vaccination (n = 56) and RT-PCR confirmed influenza infection (n = 158) cases. Lastly, we analyzed sera collected from 377 individual that exhibited acute respiratory illness (ARI) in 2020.
Results: This 41-plex assay has high sensitivity and specificity in detecting SARS-CoV-2 infections. It differentiated SARS-CoV-2 vaccination (antibody responses only to spike protein) from infection (antibody responses to both spike and nucleoprotein). No cross-reactive antibodies were detected to SARS-CoV-2 from influenza vaccination and infection, and vice versa, suggesting no interaction between SARS-CoV-2 and influenza antibody responses. However, cross-reactive antibodies were detected between spike proteins of SARS-CoV-2 and common human coronaviruses that were removed by serum adsorption. Among 377 individual who exhibited ARI in 2020, 129 were influenza positive, none had serological evidence of SARS-CoV-2/influenza co-infections.
Conclusions: Multiplex detection of antibody landscapes can provide in-depth analysis of the antibody protective immunity to SARS-CoV-2 in the context of other respiratory viruses including influenza.
Keywords: SARS-CoV-2; antibody landscape; common human coronaviruses; influenza; multiplex detection.
. 2022 Jun 10;ciac472.
doi: 10.1093/cid/ciac472. Online ahead of print.
Multiplex Detection of Antibody Landscapes to SARS-CoV-2/Influenza/Common Human Coronaviruses Following Vaccination or Infection with SARS-CoV-2 and Influenza
Zhu-Nan Li[SUP] 1 [/SUP], Feng Liu[SUP] 1 [/SUP], Stacie Jefferson[SUP] 1 [/SUP], Lauren Horner[SUP] 1 [/SUP], Paul Carney[SUP] 1 [/SUP], Michael D L Johnson[SUP] 2 [/SUP], Jennifer P King[SUP] 3 [/SUP], Emily T Martin[SUP] 4 [/SUP], Richard K Zimmerman[SUP] 5 [/SUP], Karen Wernli[SUP] 6 [/SUP], Manjusha Gaglani[SUP] 7 8 [/SUP], Mark Thompson[SUP] 1 [/SUP], Brendan Flannery[SUP] 1 [/SUP], James Stevens[SUP] 1 [/SUP], Terrence Tumpey[SUP] 1 [/SUP], Min Z Levine[SUP] 1 [/SUP]
Affiliations
- PMID: 35684961
- DOI: 10.1093/cid/ciac472
Abstract
Background: SARS-CoV-2 and influenza viruses continue to co-circulate, representing two major public health threats from respiratory infections with similar clinical presentations. SARS-CoV-2 and influenza vaccines can also now be co-administered. However, data on antibody responses to SARS-CoV-2 and influenza co-infection, and vaccine co-administration remains limited.
Methods: We developed a 41-plex antibody immunity assay that can simultaneously characterize antibody landscapes to SARS-CoV-2/influenza/common human coronaviruses. We analyzed sera from 840 individuals (11-93 years), including sera from reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 positive (n = 218) and negative (n = 120) cases, paired sera from SARS-CoV-2 vaccination (n = 29) and infection (n = 11), and paired sera from influenza vaccination (n = 56) and RT-PCR confirmed influenza infection (n = 158) cases. Lastly, we analyzed sera collected from 377 individual that exhibited acute respiratory illness (ARI) in 2020.
Results: This 41-plex assay has high sensitivity and specificity in detecting SARS-CoV-2 infections. It differentiated SARS-CoV-2 vaccination (antibody responses only to spike protein) from infection (antibody responses to both spike and nucleoprotein). No cross-reactive antibodies were detected to SARS-CoV-2 from influenza vaccination and infection, and vice versa, suggesting no interaction between SARS-CoV-2 and influenza antibody responses. However, cross-reactive antibodies were detected between spike proteins of SARS-CoV-2 and common human coronaviruses that were removed by serum adsorption. Among 377 individual who exhibited ARI in 2020, 129 were influenza positive, none had serological evidence of SARS-CoV-2/influenza co-infections.
Conclusions: Multiplex detection of antibody landscapes can provide in-depth analysis of the antibody protective immunity to SARS-CoV-2 in the context of other respiratory viruses including influenza.
Keywords: SARS-CoV-2; antibody landscape; common human coronaviruses; influenza; multiplex detection.